Background: The persistent appearance of viral strains that causes a resistant viral infection has led to continuous trials\nfor the design and development of novel antiviral compounds. Benzoquinazoline compounds have been reported\nto exhibit an interesting antiviral activity. This work aims to study and evaluate the antiviral activity of a newly prepared\n2-thioxo-benzo[g]quinazolin-4(3H)-one series against herpes simplex (HSV-1 & 2) and coxsackievirus (CVB4).\nMethods: The antiviral activity was performed using the MTT assay, in which Vero cells (obtained from the American\nType Culture Collection, ATCC) were propagated in fresh Dulbeccoââ?¬â?¢s Modified Eagleââ?¬â?¢s Medium (DMEM) and challenged\nwith 104 doses of the virus. Thereafter, the cultures were treated simultaneously with two-fold serial dilutions of the\ntested compound and incubated at 37 Ã?°C for 48 h. Molecular docking studies were done on the CVB4 2A proteinase\nenzyme using Molegro Virtual Docker software.\nResults: The cytotoxicity (CC50), effective concentration (EC50) and the selectivity index (SI) values were determined.\nBased on their EC50 values, a number of the investigated compounds demonstrated weak to moderate activity relative\nto their parents. Accordingly, compounds 5ââ?¬â??9, 11, 15ââ?¬â??18, 21, 22, 24, 25, 27 and 28 were active against CVB4,\nand compounds 5 and 24 were active against HSV-1 and 2 in comparison to ribavirin and acyclovir, which were used\nas reference drugs.\nConclusion: The obtained results gave us some useful insights about the characteristic requirements for future trials\nto build up and design more active and selective antiviral 2-thioxo-benzo[g]quinazolin-4(3H)-one agents.
Loading....